ⅢB/Ⅳ期肺癌患者放疗前后中医辨证分型与RAD51的关系

摘要
图/表
参考文献(20)
相关文章 (15)

全文: PDF (693 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨ⅢB/Ⅳ期非小细胞肺癌（NSCLC）患者放射治疗前后中医辨证分型与RAD51之间的关系。方法选择2015年5月～2018年5月解放军联勤保障部队第四七六医院肿瘤科收治的ⅢB/Ⅳ期NSCLC患者85例，在放疗前后给予中医辨证分型，并通过酶联免疫吸附测定试验检测患者血清RAD51水平。比较NSCLC患者放疗后中医证型变化情况、临床疗效、放射性肺炎发生情况、RAD51表达变化情况及放疗疗效与RAD51的关系。结果 NSCLC患者放疗后肺郁痰瘀、阴虚痰热、脾虚痰湿证型比例与放疗前比较，差异有统计学意义（P ＜ 0.05或P < 0.01）。不同证型患者临床疗效差异有统计学意义（P ＜ 0.05），放射性肺炎分级差异无统计学意义（P ＞ 0.05）。放疗后肺郁痰瘀、阴虚痰热、脾虚痰湿证型患者RAD51表达水平明显低于放疗前，差异有高度统计学意义（P ＜ 0.01），气阴两虚证患者放疗前后RAD51表达水平差异无统计学意义（P ＞ 0.05）。结论放疗前后中医辨证分型和RAD51表达情况对预测NSCLC放疗疗效具有重要意义。放疗后RAD51表达情况可以作为中医辨证分型的依据。RAD51与中医证型可以相辅相成，共同指导个体化放疗。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	黄倩1 解方为2

关键词 ：非小细胞肺癌, 放疗, 辨证, RAD51

Abstract：Objective To investigate the relationship between traditional Chinese medicine syndrome differentiation and serum levels of RAD51 in patients with stage ⅢB/Ⅳ non-small cell lung cancer (NSCLC) before and after radiotherapy. Methods From May 2015 to May 2018, 85 patients with stage ⅢB/Ⅳ NSCLC admitted to the Department of Oncology of No.476 Hospital of the Joint Logistics Team of PLA were selected. The syndrome differentiation of traditional Chinese medicine was carried out in these NSCLC patients before and after radiotherapy, and serum levels of RAD51 were measured by the enzyme-linked immunosorbent assay method. The changes of traditional Chinese medicine syndromes, clinical efficacy, occurrence of radioactive pneumonia, expression changes of RAD51 and the relationship between radiotherapy efficacy and RAD51 in NSLCL patients were compared. Results After radiotherapy, the percentage of NSLCL patients with syndrome of lung stagnation and phlegm and blood stasis, yin deficiency phlegm heat, spleen deficiency with damp phlegm had statistically significant differences compared with those before radiotherapy (P ＜ 0.05 or P < 0.01). The differences of clinical efficacy in different syndrome types were statistically significant (P ＜ 0.05). There was no statistically significant difference in the classification of radiation pneumonitis (P ＞ 0.05). After radiotherapy, the expression of RAD51 in patients with the syndrome of lung stagnation phlegm and blood stasis, yin deficiency phlegm heat, spleen deficiency with damp phlegm were significantly lower than those before radiotherapy, the differences were highly statistically significant (P ＜ 0.01). There was no significant difference in the expression of RAD51 in the patients with syndrome of deficiency of both qi and yin before and after radiotherapy (P ＞ 0.05). Conclusion Traditional Chinese medicine syndrome differentiation and RAD51 expression before and after radiotherapy are important for predicting the efficacy of NSCLC radiotherapy. The expression of RAD51 after radiotherapy can be used as the basis of traditional Chinese medicine syndrome differentiation. RAD51 and traditional Chinese medicine syndromes can complement each other to guide individualized radiotherapy. The expression of RAD51 after radiotherapy can be used as the evidence of traditional Chinese medicine syndrome differentiation. RAD51 and traditional Chinese medicine syndromes complement each other and serve as an effective way to guide individualized radiotherapy.

Key words： Non-small cell lung cancer Radiotherapy Syndrome differentiation RAD51

基金资助:福建省自然科学基金面上项目（2016J01579、2017J01329）。

通讯作者: 解方为（1971.10-），男，博士，副主任医师，主要从事恶性肿瘤中西医结合治疗研究。

作者简介: 黄倩（1986.8-），女，硕士，主要从事恶性肿瘤中西医结合治疗研究。

引用本文:

黄倩1 解方为2. ⅢB/Ⅳ期肺癌患者放疗前后中医辨证分型与RAD51的关系[J]. 中国医药导报, 2019, 16(23): 102-105.
HUANG Qian1 XIE Fangwei2. Relationship between traditional Chinese medicine syndrome differentiation and RAD51 in stage ⅢB/Ⅳ non-small cell lung cancer patients before and after radiotherapy. 中国医药导报, 2019, 16(23): 102-105.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2019/V16/I23/102

[1] DeSantis CE，Lin CC，Mariotto AB，et al. Cancer treatment and survivorship statistics [J]. CA Cancer J Clin，2014， 64（4）：252-271.
[2] Siegel RL，Miller KD，Jemal A. Cancer statistics，2018 [J]. CA Cancer J Clin，2018，68（1）：7-30.
[3] Petrelli F，Ghidini A，Cabiddu M，et al. Addition of radiotherapy to the primary tumour in oligometastatic NSCLC：A systematic review and meta-analysis [J]. Lung Cancer，2018，126：194-200.
[4] 邓小茜，戈伟.立体定向放射治疗早期非小细胞肺癌的研究进展[J].中国医药导报，2017，15（33）：28-31.
[5] Zhang M，Gao C，Yang Y，et al. Long noncoding RNA CRNDE/PRC2 participated in the radiotherapy resistance of human lung adenocarcinoma through targeting p21 expression [J]. Oncol Res，2018，26（8）：1245-1255.
[6] Zhang Z，Huo H，Liao K，et al. RPA1 downregulation enhances nasopharyngeal cancer radiosensitivity via blocking RAD51 to the DNA damage site [J]. Exp Cell Res，2018， 371（2）：330-341.
[7] Maranto C，Udhane V，Hoang DT，et al. STAT5A/B blockade sensitizes prostate cancer to radiation through inhibition of RAD51 and DNA repair [J]. Clin Cancer Res，2018， 24（8）：1917-1931.
[8] King HO，Brend T，Payne HL，et al. RAD51 is a selective DNA repair target to radiosensitize glioma stem cells [J]. Stem Cell Reports，2017，8（1）：125-139.
[9] Gachechiladze M，Škarda J，Kolek V，et al. Prognostic and predictive value of loss of nuclear RAD51 immunoreactivity in resected non-small cell lung cancer patients [J]. Lung Cancer，2017，105：31-38.
[10] Nakanoko T，Saeki H，Morita M，et al. Rad51 expression is a useful predictive factor for the efficacy of neoadjuvant chemoradiotherapy in squamous cell carcinoma of the esophagus [J]. Ann Surg Oncol，2014，21（2）：597-604.
[11] Cortez MA，Valdecanas D，Niknam S，et al. In vivo delivery of miR-34a sen-sitizes lung tumors to radiation through RAD51 regulation [J]. Mol Ther Nucleic Acids，2015，4（12）：e270.
[12] 黄伟，钱梦，谢鸣.肿瘤放射治疗配合中药增效减毒的临床研究进展[J].中国药师，2017，20（8）：1374-1381.
[13] 汤钊猷.现代肿瘤学[M].上海：复旦大学出版社，2011：100-115.
[14] 周岱翰.中医肿瘤学[M].北京：中国中医药出版社，2011.
[15] de Kock I，Mirhosseini M，Lau F，et al. Conversion of Karnofsky Performance Status（KPS）and Eastern Cooperative Oncology Group Performance Status（ECOG）to palliative performance scale（PPS），and the interchangeability of PPS and KPS in prognostic tools [J]. J Palliat Care，2013， 29（3）：163-169.
[16] Pierson C，Grinchak T，Sokolovic C，et al. Response criteria in solid tumors（PERCIST/RECIST）and SUVmax in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy [J]. Radiat Oncol，2018，13（1）：34.
[17] Tucker SL，Jin H，Wei X，et al. Impact of toxicity grade and scoring system on the relationship between mean lung dose and risk of radiation pneumonitis in a large cohort of patients with non-small cell lung cancer [J]. Int J Radiat Oncol Biol Phys，2010，77（3）：691-698.
[18] Huang Q，Xie F，Ouyang X. Predictive SNPs for radiation-induced damage in lung cancer patients with radiotherapy： a potential strategy to individualize treatment [J]. Int J Biol Markers，2015，30（1）：e1-e11.
[19] Huang Q. Predictive relevance of ncRNAs in non-small-cell lung cancer patients with radiotherapy： a review of the published data [J]. Biomark Med，2018，12（10）：1149-1159.
[20] Gachechiladze M，Škarda J，Soltermann A，et al. RAD51 as a potential surrogate marker for DNA repair capacity in solid malignancies [J]. Int J Cancer，2017，141（7）：1286-1294.